CNS TumorNEMONCT07236840
Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors
An observational study of CNS Tumor and Artificial Intelligence (AI), run by Tata Memorial Centre at 1 site in India.
Trial summary
The goal of this observational study is to evaluate the feasibility and accuracy of a self-administered remote neurological examination using the "Iskhaa" mobile application in patients with brain tumors aged above 5 years who are able to follow app-based instructions. The main questions it aims to answer are: 1. Read more about this study
- Who is it for?
- Ages 5 years and older
- Conditions the study is for
- CNS Tumor, Artificial Intelligence (AI), Glioma
- What is being tested?
- Neurological assessment
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 600 participants
- Where
- 1 siteIndia
- Study dates
- 20 Feb 2026to 5 Nov 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with brain tumors.
Who may be able to join
- Diagnosis of brain tumors (histopathology/ radiology).
- Age > 5 years
- Patient or caregiver have access to an android smart phone and is able to install the mobile application.
- Expected survival more than 6 months during study accrual.
- Signing patient consent or parent consent/ child assent form (as appropriate).
Who cannot join
- Patient or caregiver is not reliable to follow instructions or use the mobile application.
- Patient with severe cognitive or psychiatric issues causing difficulty in using the app or follow instructions.
- Karnofsky Performance Status (KPS) or Lansky Performance Status LPS) <50.
- Terminal illness with expected life expectancy (<6 months).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Dr Archya Dasgupta, Radiation Oncology, MD contact
India1 site, 1 recruiting
- Recruiting
Tata Memorial Centre
Mumbai, Maharashtra, 400012
Dr Archya Dasgupta, MD, 8097081506, archya1010@gmail.com
Dr Archya Dasgupta, MD
About this study
The goal of this observational study is to evaluate the feasibility and accuracy of a self-administered remote neurological examination using the "Iskhaa" mobile application in patients with brain tumors aged above 5 years who are able to follow app-based instructions.
The main questions it aims to answer are:
Read more
- Development of a mobile application equipped with symptom assessment and recording videos as patients perform specific neurological tasks.
- Development and validation of the AI model to detect functional changes and predict subsequent neurological deterioration.
Participants will:
- Use the Iskhaa mobile application to perform guided self-neurological examinations following pre-recorded video instructions.
- Complete EORTC QLQ-C30 and BN20 questionnaires for quality of life assessment.
- Record and upload videos (e.g., speech, walking, limb movements) using their mobile camera for analysis.
- In Phase 1 (onsite), 100 participants will use the app under supervision to ensure usability and accuracy.
- In Phase 2 (offsite), 500 participants will use the app independently at home for monthly self-assessments, with reminders and follow-up support.
- Continue routine clinic visits every 3-6 months and imaging every 6-12 months as per standard clinical care.
The study will compare app-recorded data with physician assessments to determine agreement and validity of remote neurological monitoring using artificial intelligence analysis.
Read the detailed description
The mobile application "Iskhaa" will be developed in collaboration with the Electronics Division, Bhabha Atomic Research Centre (BARC). The application will be compatible with Android version 8.0 or above. The software will have two components-mobile application (for patients and healthcare providers) and a desktop application (for healthcare providers). The data recorded using the app will be stored in a secured hospital server accessible via the hospital network. The sample of different clinical features to be recorded by the application is included in Annexure A. The mobile application will be initially developed in English and subsequently translated to Hindi, Marathi, and Bengali in upgraded versions over initial 3-6 months. Pre-recorded videos will be used to guide the patients in repeating the actions that will be recorded for neurological examination. Examples of such instructions will include speech (patient asked to speak fixed sentences), gait, e.g., walking 20 steps, tandem walking to check cerebellar function, lifting individual limbs, etc. In addition, the European Organisation for Research and Treatment of Cancer (EORTC) quality of life core questionnaire (QLQ-C30) and brain cancer module (BN20) will be available in the mobile application. The recorded symptoms will be stored in a secured database, and the study investigators will have access to review them using either mobile or desktop applications. Once an assessment (either onsite or onsite) is completed, the data will be updated electronically at the central site housed in Tata Memorial Centre, and the investigator will receive a reminder. Version upgradation for better improvement of the application interface for better user compliance and software updates will be done periodically as required. A sample of the application interface is provided in the diagram below.
Patients aged more than 5 years with a diagnosis of brain tumor, having an expected life expectancy of more than 6 months, and able to follow instructions of the mobile application will be screened for the study. They will be accrued after signing a written consent or assent form as appropriate. The initial phase of the study will include an onsite assessment of 100 patients who will be required to use the mobile application to assess symptoms and record videos for neurological functional assessment. In this phase, the application will be installed on specific mobile phones (not belonging to the patient). After performing the evaluation, all the patients will be evaluated by the responsible physician in the clinic, who will follow standard protocols. A detailed neurological examination will be conducted to cover all aspects of the symptoms and functional assessment as available in the mobile application. The primary purpose of the on-site evaluation is to provide any technical support for the application use by the in-house team before installation on mobile devices for patients to allow seamless transition and use. The second phase of assessment will include 500 patients who will perform the virtual examination (off-site). The mobile application will be installed on individual phones when consent is obtained for study participation. Patients will be required to undergo monthly assessments at home with reminders set up for performing the timely evaluations, and they will be reminded by telephone in case of delay in taking the assessment by 7 days. Patients and caregivers will be able to record and upload the video using the mobile camera. Additionally, patients will be instructed to undergo self-assessments (unscheduled) in case of symptomatic worsening. Patients will continue follow-up in the clinic for physical evaluation every 3-6 months as per standard institutional practice and imaging scheduled every 6-12 monthly specific for the histological diagnosis or as mandated clinically in case of neurological worsening as decided by the responsible physician without any influence of the study participation.
All the data completed will be available for study investigators to retrieve. The symptomatology assessment will be presented as descriptive statistics and serial changes will be analyzed. The data recorded using the app will be correlated with the assessment by the physician during each clinic visit. Computational analysis will be performed for all the individual tasks undertaken by the patient and recorded in the video format. Neurological functioning (e.g., gait and movement) will be recorded using artificial intelligence algorithms with a hybrid model that combines convolutional neural networks (CNNs) and vision transformers (ViTs). The video data will undergo preprocessing steps to extract relevant features, such as silhouettes, skeletal representations, or pose key points, using advanced pose estimation tools like OpenPose. Each frame will be processed by a CNN backbone, such as ResNet or EfficientNet, to extract low-level spatial features. These features will then be fed into a Vision Transformer module, which will model global temporal dependencies across the sequence of frames, providing a robust representation of the patient's gait. This combined framework will enable the detection of subtle anomalies, abnormalities, or variations in gait, which are critical for clinical monitoring. The model will be trained and validated using video data captured from diverse patient populations, and clinical scenarios. By leveraging the granularity of high-speed footage, the model will aim to deliver high-precision outputs such as gait classification, anomaly detection, or parameter regression tailored to the specific needs of applications. The integration of state-of-the-art techniques, such as 3D Vision Transformers for enhanced spatiotemporal analysis, will ensure the model's robustness and generalizability. Furthermore, Explainable AI (XAI) methodologies will be incorporated to interpret the model's predictions, providing actionable insights and fostering trust in the system.
- Conditions
- CNS Tumor, Artificial Intelligence (AI), Glioma, Digital Health
- Being tested
- Neurological assessment
- Keywords
- neurological examination, mobile application, brain tumors
- Medical subject headings
- Central Nervous System Neoplasms, Glioma, Brain Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neurological assessmentBehavioural
This assessment will include Speech, Cerebellar function and Quality of Life questionnaires using mobile application.
What is being measured
The primary outcome is the main question the study is designed to answer.
Development of a mobile application equipped with symptom assessment and recording videos as patients perform specific neurological tasks.
Correlation between patients self assessment of neurological status utilizing the application and the physician-based evaluation will be done using Cohen kappa statistics.
Measured: 2 years
Prediction of neurological status using mobile application
Regression analysis of neurological symptoms recorded using application with disease status (recurrence or no recurrence).
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2025
- Study start20 Feb 2026
- Primary completion1 Nov 2027 (estimated)
- Study completion5 Nov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CNS TumorStudies of the same condition, open and under way.
- More trials run by Tata Memorial CentreThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tata Memorial Centre
- Sponsor type
- University, hospital or other
- Collaborators
- Bhabha Atomic Research Centre
- Responsible party
- Principal investigator, Dr Archya Dasgupta, Tata Memorial Centre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07236840
- Sponsor's protocol ID
- 4752
- Acronym
- NEMO
- Status last verified
- Feb 2026
- First submitted
- 14 Nov 2025
- Last updated
- 24 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors
- ClinicalTrials.gov ID
- NCT07236840
- Acronym / sponsor ID
- NEMO / 4752
- Conditions
- CNS Tumor, Artificial Intelligence (AI), Glioma, Digital Health
- Keywords
- neurological examination, mobile application, brain tumors
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- Tata Memorial CentreUniversity, hospital or other
- Collaborators
- Bhabha Atomic Research Centre
- Study start
- 20 Feb 2026 (actual)
- Primary completion
- 1 Nov 2027 (estimated)
- Study completion
- 5 Nov 2027 (estimated)
- First posted
- 19 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to evaluate the feasibility and accuracy of a self-administered remote neurological examination using the "Iskhaa" mobile application in patients with brain tumors aged above 5 years who are able to follow app-based instructions.
The main questions it aims to answer are:
- Development of a mobile application equipped with symptom assessment and recording videos as patients perform specific neurological tasks.
- Development and validation of the AI model to detect functional changes and predict subsequent neurological deterioration.
Participants will:
- Use the Iskhaa mobile application to perform guided self-neurological examinations following pre-recorded video instructions.
- Complete EORTC QLQ-C30 and BN20 questionnaires for quality of life assessment.
- Record and upload videos (e.g., speech, walking, limb movements) using their mobile camera for analysis.
- In Phase 1 (onsite), 100 participants will use the app under supervision to ensure usability and accuracy.
- In Phase 2 (offsite), 500 participants will use the app independently at home for monthly self-assessments, with reminders and follow-up support.
- Continue routine clinic visits every 3-6 months and imaging every 6-12 months as per standard clinical care.
The study will compare app-recorded data with physician assessments to determine agreement and validity of remote neurological monitoring using artificial intelligence analysis.
Detailed description
The mobile application "Iskhaa" will be developed in collaboration with the Electronics Division, Bhabha Atomic Research Centre (BARC). The application will be compatible with Android version 8.0 or above. The software will have two components-mobile application (for patients and healthcare providers) and a desktop application (for healthcare providers). The data recorded using the app will be stored in a secured hospital server accessible via the hospital network. The sample of different clinical features to be recorded by the application is included in Annexure A. The mobile application will be initially developed in English and subsequently translated to Hindi, Marathi, and Bengali in upgraded versions over initial 3-6 months. Pre-recorded videos will be used to guide the patients in repeating the actions that will be recorded for neurological examination. Examples of such instructions will include speech (patient asked to speak fixed sentences), gait, e.g., walking 20 steps, tandem walking to check cerebellar function, lifting individual limbs, etc. In addition, the European Organisation for Research and Treatment of Cancer (EORTC) quality of life core questionnaire (QLQ-C30) and brain cancer module (BN20) will be available in the mobile application. The recorded symptoms will be stored in a secured database, and the study investigators will have access to review them using either mobile or desktop applications. Once an assessment (either onsite or onsite) is completed, the data will be updated electronically at the central site housed in Tata Memorial Centre, and the investigator will receive a reminder. Version upgradation for better improvement of the application interface for better user compliance and software updates will be done periodically as required. A sample of the application interface is provided in the diagram below.
Patients aged more than 5 years with a diagnosis of brain tumor, having an expected life expectancy of more than 6 months, and able to follow instructions of the mobile application will be screened for the study. They will be accrued after signing a written consent or assent form as appropriate. The initial phase of the study will include an onsite assessment of 100 patients who will be required to use the mobile application to assess symptoms and record videos for neurological functional assessment. In this phase, the application will be installed on specific mobile phones (not belonging to the patient). After performing the evaluation, all the patients will be evaluated by the responsible physician in the clinic, who will follow standard protocols. A detailed neurological examination will be conducted to cover all aspects of the symptoms and functional assessment as available in the mobile application. The primary purpose of the on-site evaluation is to provide any technical support for the application use by the in-house team before installation on mobile devices for patients to allow seamless transition and use. The second phase of assessment will include 500 patients who will perform the virtual examination (off-site). The mobile application will be installed on individual phones when consent is obtained for study participation. Patients will be required to undergo monthly assessments at home with reminders set up for performing the timely evaluations, and they will be reminded by telephone in case of delay in taking the assessment by 7 days. Patients and caregivers will be able to record and upload the video using the mobile camera. Additionally, patients will be instructed to undergo self-assessments (unscheduled) in case of symptomatic worsening. Patients will continue follow-up in the clinic for physical evaluation every 3-6 months as per standard institutional practice and imaging scheduled every 6-12 monthly specific for the histological diagnosis or as mandated clinically in case of neurological worsening as decided by the responsible physician without any influence of the study participation.
All the data completed will be available for study investigators to retrieve. The symptomatology assessment will be presented as descriptive statistics and serial changes will be analyzed. The data recorded using the app will be correlated with the assessment by the physician during each clinic visit. Computational analysis will be performed for all the individual tasks undertaken by the patient and recorded in the video format. Neurological functioning (e.g., gait and movement) will be recorded using artificial intelligence algorithms with a hybrid model that combines convolutional neural networks (CNNs) and vision transformers (ViTs). The video data will undergo preprocessing steps to extract relevant features, such as silhouettes, skeletal representations, or pose key points, using advanced pose estimation tools like OpenPose. Each frame will be processed by a CNN backbone, such as ResNet or EfficientNet, to extract low-level spatial features. These features will then be fed into a Vision Transformer module, which will model global temporal dependencies across the sequence of frames, providing a robust representation of the patient's gait. This combined framework will enable the detection of subtle anomalies, abnormalities, or variations in gait, which are critical for clinical monitoring. The model will be trained and validated using video data captured from diverse patient populations, and clinical scenarios. By leveraging the granularity of high-speed footage, the model will aim to deliver high-precision outputs such as gait classification, anomaly detection, or parameter regression tailored to the specific needs of applications. The integration of state-of-the-art techniques, such as 3D Vision Transformers for enhanced spatiotemporal analysis, will ensure the model's robustness and generalizability. Furthermore, Explainable AI (XAI) methodologies will be incorporated to interpret the model's predictions, providing actionable insights and fostering trust in the system.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 5 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with brain tumors.
Key inclusion criteria (5 listed)
- Diagnosis of brain tumors (histopathology/ radiology).
- Age > 5 years
- Patient or caregiver have access to an android smart phone and is able to install the mobile application.
- Expected survival more than 6 months during study accrual.
- Signing patient consent or parent consent/ child assent form (as appropriate).
Key exclusion criteria (4 listed)
- Patient or caregiver is not reliable to follow instructions or use the mobile application.
- Patient with severe cognitive or psychiatric issues causing difficulty in using the app or follow instructions.
- Karnofsky Performance Status (KPS) or Lansky Performance Status LPS) <50.
- Terminal illness with expected life expectancy (<6 months).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neurological assessmentThis assessment will include Speech, Cerebellar function and Quality of Life questionnaires using mobile application. | Behavioural | – |
Primary outcome
Development of a mobile application equipped with symptom assessment and recording videos as patients perform specific neurological tasks.
Time frame: 2 years
Correlation between patients self assessment of neurological status utilizing the application and the physician-based evaluation will be done using Cohen kappa statistics.
Prediction of neurological status using mobile application
Time frame: 2 years
Regression analysis of neurological symptoms recorded using application with disease status (recurrence or no recurrence).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Feb 2026.
Related trials for CNS Tumor
RecruitingPhase 2
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
Diffuse Intrinsic Pontine Glioma, DIPG
Recruiting
68Ga-XHER2 PET/CT for HER2 Assessment
Solid Tumor (Excluding CNS), HER2
Recruiting
Effect of a Driving Pressure Adjustment Procedure for High-Frequency Jet Ventilation in Patients Undergoing Tumor Thermal Ablation in Interventional Radiology
Solid Tumor (Excluding CNS)
RecruitingPhase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Medulloblastoma Recurrent, Ependymoma Recurrent
Active, not recruitingPhase 1
Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Dr Archya Dasgupta, Radiation Oncology, MD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of CNS Tumor and Artificial Intelligence (AI), run by Tata Memorial Centre at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dr Archya Dasgupta, Radiation Oncology, MD (8097081506 ext. 91-22-24177000, archya1010@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Development of a mobile application equipped with symptom assessment and recording videos as patients perform specific neurological tasks. (time frame: 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2026; AzTrials last refreshed its copy on 26 Oct 2026.